The suppression of rat collagen-induced arthritis and inhibition of macrophage derived mediator release by liposomal methotrexate formulations

Inflammation Research

Volumn 49, Issue 4, 2000, Pages 155-161

  Williams, A ^a   Goodfellow, R ^a   Topley, N ^a   Amos, N ^a   Williams, B ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Arthritis; Interleukin 1 ; Macrophage; Prostaglandin E2

Indexed keywords

CHOLESTEROL; COLLAGEN; CYTOKINE; DISTEAROYLPHOSPHATIDYLCHOLINE; INTERLEUKIN 1BETA; LIPOSOME; MACROGOL; METHOTREXATE; PHOSPHATIDIC ACID; PHOSPHATIDYLCHOLINE; PROSTAGLANDIN E2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; MACROPHAGE; MEDIATOR RELEASE; NONHUMAN; PROSTAGLANDIN RELEASE; RAT;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS; BLOOD CELL COUNT; COLLAGEN; CYTOKINES; DINOPROSTONE; DRUG CARRIERS; INTERLEUKIN-1; LIPOSOMES; MACROPHAGES; MALE; METHOTREXATE; RATS; RATS, INBRED LEW;

EID: 0034020695     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050575     Document Type: Article

References (40)

1. [1] Fries J, Singh G, Lenert L, Furst DE. Aspirin, hydroxychloroquine and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arth and Rheum 1990; 33: 1611-5.
2. [2] Franchi F, Seminara P, Codacci-Pisane G, Aronne T, Avella A, Bonomo L. Intra-articular methotrexate in the therapy of rheumatoid arthritis. Recent Prog Med 1989; 5: 261-2.
3. [3] Wilke WS, Biro JA, Segal AM. Methotrexate in the treatment of rheumatoid arthritis and connective tissue diseases. Clev Clin J Med 1987; 54: 327-8.
4. [4] Foong WC, Green K.L. Treatment of antigen induced arthritis in rabbits with liposome-entrapped methotrexate injected intraarticularly. J Pharm Pharmacol 1992; 45: 204-9.
5. [5] Asao T, Shibata HR, Batist G, Brodt P. Eradication of hepatic metastases of carcinoma H-59 by combination chemotherapy with liposomal muramyl tripeptide, 5-fluorouracil and leucovorin. Cancer Res 1992; 52: 6254-7.
6. [6] Janoff AS. Lipids, liposomes and rationale drug design. Lab Invest 1992; 66: 655-8.
7. [7] Chopra R, Blair S, Strang J, Cervi P, Paterson KG, Goldstone AH. Liposomal amphoteracin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J Antimicrob Chemother 1991; 28 (SupplB): 93-104.
8. [8] Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol Today 1990; 11: 89-97.
9. [9] Alving CR. Liposomes as carriers of antigens and adjuvants. J Immunol Methods 1991; 140: 1-13.
10. [10] Alving CR. Delivery of encapsulated drugs to macrophages. Pharmacol Ther 1983; 22: 407-24.
11. [11] Lopez-Berestein G, Fainstein V, Hopfer RL, Juliano RL, Bodey GP. Liposomal Amphoteracin B for the treatment of systemic fungal infections in patients with cancer. J Infect Dis 1985; 4: 704-10.
12. [12] O'Sullivan MM, Powell N, French AP, Williams KE, Morgan JR, Williams BD. Inflammatory joint disease: a comparison of liposome scanning, bone scanning and radiography. Ann. Rheum. Diseases 1988; 47: 485-91.
13. [13] Williams BD, O'Sullivan MM, Saggu GS, Williams KE, Williams LA, Morgan JR. Imaging in rheumatoid arthritis using liposomes labelled with technetium. Br Med J 1986; 293: 1143-4.
14. [14] Williams BD, O'Sullivan MM, Saggu GS, Williams KE, Williams LA, Morgan JR. Synovial accumulation of technetium labelled liposomes in rheumatoid arthritis. Ann Rheum Diseases 1987; 46: 314-8.
15. [15] Love WG, Amos N, Kellaway IW, Williams BD. Specific accumulation of technetium-99m radiolabelled negative liposomes in the inflamed paws of rats with adjuvant induced arthritis. Ann Rheum Diseases 1989; 48: 143-8.
16. [16] Love WG, Amos N, Kellaway IW, Williams BD. Specific accumulation of cholesterol-rich liposomes in the inflammatory tissue of rats with adjuvant-induced arthritis. Ann Rheum Diseases 1990; 49: 611-4.
17. [17] Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols prolong the circulation time of liposomes. FEBS Lett 1990; 268: 235-7.
18. [18] Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK et al. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA. 1991; 88: 11460-4.
19. [19] Blume G, Cevc G. Liposomes for the sustained drug release in vivo. Biochim et Biophys Acta 1990; 1029: 91-7.
20. [20] Williams AS, Love WG, Williams BD. Synthesis of methotrexate-dimyristoyIphosphatidylethanolamine analogs and characterisation of methotrexate release in vitro. Int J Pharm 1992; 85: 189-97.
21. [21] Williams AS, Topley N, Amos N, Williams BD. Effect of three lipophilic methotrexate derivatives upon mediator release by lipopolysaccharide stimulated rat peritoneal macrophages. J Pharm Pharmacol 1994; 46: 291-5.
22. 2 release by lipopolysaccharide stimulated rat peritoneal macrophages. Biochim et Biophys Acta 1994; 1225: 217-22.
23. 2 production is synergistically increased in cultured human glomerular mesangial cells by combination of IL-1 and tumor necrosis factor-α. J Immunol 1989; 143: 1989-95.
24. [24] Kaever V, Goppelt-Streube M, Resch K. Enhancement of eicosanoid synthesis in mouse peritoneal macrophages by the organic mercury compound thiomersal. Prostaglandins 1988; 35: 885-902.
25. [25] Bristow AF, Mosley K, Poole S. Interleukin-1β production in vivo and in vitro in rats and mice measured using specific immunoradiometric assays. J Mol Endocrinol 1991; 7: 1-7.
26. [26] Morgan K, Reeve-Stephenson JO, Denton AJ, Freemont AJ. Type II collagen induced arthritis: comparison of histological changes in arthritis-susceptible and arthritis-resistant rats. Clin Exp Rheumatol 1992; 10: 109-16.
27. [27] Bresnihan B. The synovial lining cells in chronic arthritis. Br J Rheumatol 1992; 31: 433-6.
28. [28] Hopkins SJ. Cytokines and eicosanoids in rheumatic diseases. Ann Rheum Dis 1991; 49: 207-11.
29. [29] Malone DG, Wahl SM, Tsokos M, Cattell H, Decker JL, Wilder RL. Immune function in severe, active rheumatoid arthritis. A relationship between peripheral blood mononuclear cell proliferation to soluble antigens and synovial tissue immunohistologic characterisation. J Clin Invest 1984; 74: 1173-85.
30. [30] Shore A, Jaglal S, Keystone EC. Enhanced interleukin-1 generation by monocytes in vitro is temporarily linked to an early event in the onset of exacerbation of rheumatoid arthritis. Clin Exp Immunol 1986; 65: 293-302.
31. [31] Williams AS, Camilleri JP, Williams BD. Suppression of adjuvant-induced arthritis by liposomally conjugated methotrexate in the rat. Br J Rheumatol 1994; 33: 530-3.
32. [32] Williams AS, Camilleri JP, Amos N, Williams BD. Differential effects of methotrexate and liposomally conjugated methotrexate in rat adjuvant induced arthritis. Clin Exp Immunol 1995; 102: 560-5.
33. [33] Williams RO, Williams DG, Feldmann M, Maini RN. Increased limb involvement in murine collagen-induced arthritis following treatment with anti-interferon-gamma. Clin Exp Immunol 1993; 92: 323-7.
34. [34] Cooper WO, Fava RA, Gates CA, Cremer MA, Townes AS. Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumor necrosis factor or transforming growth factor-beta. Clin Exp Immunol 1992; 89: 244-50.
35. [35] Hom JT, Bendele AM, Carlson DG. In vivo administration with IL-1 accelerates the development of collagen-induced arthritis in mice. J Immunol 1988; 141: 834-41.
36. [36] Hom JT, Gliszczynski VL, Cole HW, Bendele AM. Interleukin-1 mediated acceleration of type II collagen-induced arthritis: Effects of anti-inflammatory or anti-arthritis drugs. Agents and Actions 1991; 33: 300-9.
37. [37] Van Den Berg WB, Joosten LAB, Helsen M, Van De Loo FAJ. Ameloration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 1994; 95: 237-43.
38. [38] Williams RO, Mason LJ, Feldmann M, Maini R. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994; 91: 2762-6.
39. [39] Williams RO, Feldmann M, Maini R. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89: 9784-8.
40. [40] Geiger T, Towbin H, Cosenti-Vargas A, Zingel O, Arnold J, Rordorf C et al. Neutralization of interleukin-1β activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response. Clin Exp Rheumatol 1993; 11: 515-22.